Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT

PHASE3CompletedINTERVENTIONAL
Enrollment

314

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

January 2, 2023

Study Completion Date

March 30, 2024

Conditions
Hematological MalignanciesHematopoietic Stem Cell Transplantation
Interventions
OTHER

PBSCs

PBSCs harvest is performed from day 5 of G-CSF to obtain at least 7.0×10\^8 total nucleated cells/kg recipient ideal body weight.

OTHER

Cord

The criteria for cord selection included the following: (1) ≥3 of 6 HLA loci , (2) blood type matches, (3) contained a minimum cell count of 0.3×10\^8 nucleated cells/kg and 0.15×10\^6 CD34-positive cells/kg before freezing. The third party UCB will be infused the day after infusion of PBSCs.

OTHER

BMSCs

BMSCs of donor will be collected and infused at least 0.5×10\^8 total nucleated cells/kg recipient ideal body weight the day after PBSCs infusion.

Trial Locations (1)

510515

Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

collaborator

Hunan Provincial People's Hospital

OTHER

collaborator

The Seventh Affiliated Hospital of Sun Yat-sen University

OTHER

collaborator

First People's Hospital of Chenzhou

OTHER

collaborator

Dongguan People's Hospital

OTHER_GOV

collaborator

The First People's Hospital of Guangzhou

UNKNOWN

lead

Nanfang Hospital, Southern Medical University

OTHER